Eculizumab is given as an intravenous (IV) infusion by a healthcare professional. The administration is typically done in a hospital or clinic under the supervision of medical staff. Here’s how it’s generally used:

1. Preparation for Treatment: The healthcare provider will prepare the medication for the infusion based on the prescribed dosage and schedule.
   
   
2. Infusion Process: The infusion will be administered over a 60-minute period. The healthcare team will monitor you closely during the infusion to check for any reactions.
   
   
3. Follow-Up Doses: After the initial loading doses, you will receive maintenance doses every 2 weeks. Regular monitoring and check-ups are necessary during treatment.
   
   

Precautions: During the infusion, inform your healthcare provider if you experience any discomfort or signs of side effects, such as fever, chills, or headache.

Eculizumab works by inhibiting the complement system, which is part of the body’s immune system. The complement system helps the body fight infections by attacking and destroying foreign cells, including bacteria. However, in certain diseases, this system can become overactive and start attacking the body’s own cells, leading to inflammation and tissue damage.

• Inhibition of Complement C5: Eculizumab specifically binds to complement protein C5, preventing its activation and the subsequent formation of C5a and C5b-9 (the membrane attack complex).
  
  
• Prevention of Inflammation: By blocking C5 activation, eculizumab reduces inflammation, tissue damage, and destruction of red blood cells in diseases like PNH and aHUS.
  
  

Reduction of Hemolysis: In conditions like PNH, where red blood cells are destroyed prematurely (hemolysis), eculizumab helps prevent this destruction and reduce the risk of complications like anemia and fatigue.

While Eculizumab is generally well-tolerated, it may cause side effects in some individuals:

• Common Side Effects:
  
  
  • Headache
    
    
  • Fever
    
    
  • Nausea
    
    
  • Fatigue
    
    
  • Cold-like symptoms (such as sore throat, stuffy nose)
    
    
• Serious Side Effects:
  
  
  • Infections: Eculizumab can increase the risk of serious infections, particularly meningococcal disease (a bacterial infection that can lead to meningitis). Vaccination is required before starting treatment.
    
    
  • Allergic Reactions: Rarely, patients may experience severe allergic reactions, such as rash, swelling, or difficulty breathing.
    
    
  • Infusion Reactions: Some people may have reactions during the infusion, such as chills, fever, or difficulty breathing.
    
    
• Other Effects:
  
  
  • Low Blood Pressure: Some patients may experience a drop in blood pressure during the infusion.
    
    

Liver Enzyme Changes: In rare cases, liver function may be affected.

Before starting Eculizumab, consider the following warnings:

• Infection Risk: Eculizumab can increase the risk of serious infections, particularly meningococcal infections. Vaccination against meningococcal disease is required prior to starting treatment, and patients should continue to be vigilant for symptoms of infection during treatment.
  
  
• Monitor for Side Effects: Due to the risk of infections, it’s important to monitor for symptoms such as fever, severe headache, neck stiffness, or rash.
  
  
• Pregnancy and Breastfeeding: There is limited data on the use of eculizumab during pregnancy. It should be used during pregnancy only if clearly needed. Consult your healthcare provider if you are pregnant or breastfeeding.
  
  

Immune System: Since eculizumab affects the immune system, it should be used with caution in patients who have weakened immune systems or are prone to infections.

• Vaccination Requirements: Since eculizumab reduces immune system function, patients must be vaccinated against meningococcal infection before starting treatment. Other vaccines like pneumococcal and hemophilus influenzae should also be given.
  
  
• Infections: Using eculizumab may increase the risk of serious infections like meningococcal disease. It is essential to monitor for signs of infection during treatment.
  
  

Immunosuppressive Medications: Combining eculizumab with other immunosuppressive medications may increase the risk of infections.

The recommended dosage of Eculizumab varies based on the condition being treated:

• For Paroxysmal Nocturnal Hemoglobinuria (PNH):
  
  
  • Loading dose: 600 mg IV every week for 4 weeks.
    
    
  • Maintenance dose: 900 mg IV every 2 weeks after the loading dose.
    
    
• For Atypical Hemolytic Uremic Syndrome (aHUS):
  
  
  • Loading dose: 600 mg IV every week for 4 weeks.
    
    
  • Maintenance dose: 900 mg IV every 2 weeks after the loading dose.
    
    
• For Neuromyelitis Optica Spectrum Disorder (NMOSD):
  
  
  • Loading dose: 600 mg IV every week for 4 weeks.
    
    

Maintenance dose: 900 mg IV every 2 weeks after the loading dose.

Eculizumab is a prescription-only medication that must be administered under the supervision of a healthcare professional. It is not available over-the-counter and requires a prescription from a doctor. The healthcare provider will assess whether eculizumab is appropriate based on the patient’s specific condition and medical history.

• What is Eculizumab?
  Eculizumab is a prescription monoclonal antibody medication that inhibits part of the immune system known as the complement pathway.

• What conditions does Eculizumab treat?
  It is used for Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), and Neuromyelitis Optica Spectrum Disorder (NMOSD).

• How does Eculizumab work?
  It blocks complement protein C5, preventing the formation of membrane attack complex that damages red blood cells and tissues.

• Is Eculizumab an immunosuppressant?
  Yes, it suppresses part of the immune system, which can increase infection risks.

• How is Eculizumab given?
  It is administered by intravenous (IV) infusion under medical supervision.

• How often is Eculizumab taken?
  The schedule usually starts with weekly doses, followed by maintenance infusions every 2 weeks.

• What are the common side effects of Eculizumab?
  Headache, nausea, diarrhea, back pain, and infusion reactions.

• What serious risks are associated with Eculizumab?
  It increases the risk of meningococcal infections, which can be life-threatening.

• Do patients need vaccines before starting Eculizumab?
  Yes, meningococcal vaccination is required before starting treatment.

• Is Eculizumab safe during pregnancy?
  Safety is not fully established; use only if benefits outweigh risks.

• Can children use Eculizumab?
  Yes, it is approved for pediatric use in certain conditions like aHUS.

• Is Eculizumab a lifelong treatment?
  In many cases, yes—patients may need to continue indefinitely to control disease activity.

• What happens if a dose is missed?
  Patients should contact their doctor immediately; delaying treatment can cause disease relapse.

• Are there alternatives to Eculizumab?
  Yes, Ravulizumab (Ultomiris) is a longer-acting alternative.

• Why is Eculizumab so expensive?
  It is a rare-disease biologic drug with complex manufacturing, leading to very high costs.

• Is Eculizumab available as a generic?
  No, currently no generic or biosimilar versions are widely available.

• How long does Eculizumab take to work?
  Patients with PNH may see improvement within weeks, but response varies by condition.

• Who should not take Eculizumab?
  Patients with unresolved meningococcal infection or those not vaccinated against it.

• Can Eculizumab interact with other medications?
  It may increase infection risk when combined with other immunosuppressants; always consult a doctor.

• How is Eculizumab stored and supplied?
  It is supplied in single-use vials and must be stored refrigerated until prepared for infusion.